Pharmaceuticals
Despite nationwide basic stroke treatment coverage, delays accessing advanced stroke care in Vietnam vary by region, new report finds
Patients in Vietnam's Southwest region and Mekong Delta can travel up to ten hours for advanced stroke care; Vietnamese experts point to a public-private model in Can Tho as a way to close that gap. HO CHI MINH CITY, Vietnam, Sept. 2, 2026 /PRNewswire/ -- Delays occurring before patients reach a...
Workforce shortages and limited public hospital capacity remain major barriers to stroke care in the Philippines, new report finds
Filipino experts call for equipping more public hospitals with advanced imaging technology, stronger EMS infrastructure and greater investment in specialist training to close these gaps MANILA, Philippines, Sept. 2, 2026 /PRNewswire/ -- Workforce shortages and limited public hospital capacity re...
Delays before patients reach stroke centres remain a major barrier to timely treatment in Malaysia, new report finds
Malaysia experts call for better public awareness of stroke symptoms, standardised hospital imaging protocols and expanded access to specialist care beyond major urban centres KUALA LUMPUR, Malaysia, Sept. 2, 2026 /PRNewswire/ -- Delays occurring before patients reach stroke centres remain a maj...
Delays Before Patients Reach Stroke Centers Still Hinder Timely Treatment Across Southeast Asia, Siemens Healthineers Report Finds
New research commissioned by Siemens Healthineers shows transportation delays, slow reporting processes as leading barriers to timely stroke diagnosis. * Stronger referral networks, public awareness, AI-enabled diagnostics, coordinated care are key to strengthening stroke system readiness acros...
HEC Group Enters Strategic Partnerships in Macau to Advance the Internationalization of Cordyceps Sinensis
MACAU, Sept. 2, 2026 /PRNewswire/ -- HEC Group has entered into strategic partnerships with MCCY Science & Greater Health Manufactory (operating regionally as Seed Scientific Research International Limited) and Longtai Health to strengthen the production, commercialization and international deve...
Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway
* The Phase 3 BiPASS™ study of Illuccix® and Gozellix® for prostate cancer imaging in the pre-biopsy setting has completed enrollment of 350 patients. * Telix has positively engaged with the FDA on a New Drug Application (NDA) pathway in the U.S. that would support new product reimbursement an...
Haier Biomedical Highlights Automated Biostorage and Connected Pharma Solutions at ISPE Singapore 2026
Haier Biomedical Accelerates Its Transformation into an Intelligent
Biopharmaceutical Infrastructure Platform at ISPE Singapore 2026
SINGAPORE, Sept. 1, 2026 /PRNewswire/ -- Haier Biomedical
Haier Biomedical Highlights Automated Biostorage and Connected Pharma Solutions at ISPE Singapore 2026
Haier Biomedical Accelerates Its Transformation into an Intelligent
Biopharmaceutical Infrastructure Platform at ISPE Singapore 2026
SINGAPORE, Sept. 1, 2026 /PRNewswire/ -- Haier Biomedical
REJURAN COSMETICS Expands Across Canada with Nationwide Sephora Launch
Premium derma-cosmetic brand from PharmaResearch, the Korean pharmaceutical company behind the globally recognized REJURAN® skin booster available in more than 50 countries, will launch in Sephora Canada stores. SEOUL, South Korea, Sept. 1, 2026 /PRNewswire/ -- REJURAN COSMETICS, the premium der...
Simcere Zaiming Enters Exclusive License Agreement with Roche for SIM0660 Global Development
NANJING, China, Sept. 1, 2026 /PRNewswire/ -- Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group (2096.HK) today announced that it has entered into an exclusive global licensing agreement with Roche for the development and commercialization of SIM0660, a tri-specific antibody targeting...
Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy
Paxalisib Monotherapy Significantly Reduced Tumor Burden in Pre-Clinical Model of MSS/pMMR Colorectal Cancer, With the Addition of Pembrolizumab Driving a Further Reduction Paxalisib Was Well Tolerated as Monotherapy and in Combination with Checkpoint Inhibition Kazia is Preparing to Advance Pa...
Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer
Preclinical Data Show Paxalisib Combined With Standard-of-Care Therapy Is Well Tolerated and Produces Statistically Significant Antitumor Activity Three-Arm Expansion of the Ongoing TNBC Trial Will Evaluate Paxalisib Plus Fulvestrant, With Palbociclib, Versus Standard-of-Care First Patient Expec...
OncoC4 Appoints Dr. Steve Chen, JD, PhD as General Counsel
ROCKVILLE, Md., Sept. 1, 2026 /PRNewswire/ -- OncoC4, Inc., a late clinical-stage biopharmaceutical company developing novel medicines for cancer and neurodegenerative diseases, today announced the appointment of Steve Chen, JD, PhD, as General Counsel. Dr. Chen brings nearly two decades of lega...
JIANGXI BIO Announced 2026 Interim Results
Overseas Contract Orders Reach Nearly RMB27.4 mn and R&D Translation Gains Momentum, with the AEPC Platform Reshaping the R&D Paradigm for Equine Polyclonal Antibody Interim Results Highlights Key Financial Indicators * Revenue amounted to RMB83.3 mn; gross profit amounted to RMB60.3 mn, ...
Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering
Company to host a corporate update call Tuesday, September 1st at 8:00am ET
SYDNEY, Sept. 1, 2026 /PRNewswire/ -- Kazia Therapeutics Limited
Bausch Health Announces Availability of Solta Medical's Fraxel FTX® in Australia
The next generation in skin resurfacing technology is available to Australian health care practitioners beginning 1 September 2026 LAVAL, QC, Sept. 1, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC), a global, diversified pharmaceutical company, and its aesthetics busines...
Convergen Secures $15 Million Seed+ Financing to Advance Therapeutics for Protein Aggregation Diseases
SUZHOU, China, Aug. 31, 2026 /PRNewswire/ -- Convergen, a biotechnology company pioneering targeted protein degradation (TPD) therapies for diseases driven by pathological protein aggregates, today announced the closing of a $15 million Seed+ financing round. This round was led by MPCi, with part...
CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum
CS2009 Achieved Key Clinical Validations for Efficacy and Safety As of August 2026, updated data further confirmed the favorable safety profile of CS2009 and demonstrated strengthened efficacy across multiple key cohorts compared with the data presented at ASCO in May 2026. With expanded patient...
T-MAXIMUM B7-H3-Targeted Allogeneic CAR-T Therapy MT027 Receives FDA Fast Track Designation, Accelerating Global Development for Intracranial Solid Tumors
MT027 has previously been granted FDA Orphan Drug Designation and has entered Phase II clinical development in recurrent glioblastoma BEIJING, Aug. 31, 2026 /PRNewswire/ -- T-MAXIMUM PHARMACEUTICAL Inc. ("T-MAXIMUM") today announced that its investigational allogeneic CAR-T cell therapy MT027 ha...
Samsung Biologics publishes prospectus for PolyPeptide public tender offer
* Direct subsidiary Samsung Peptide AG acting as formal offeror of the public tender offer * Publication of offer prospectus follows pre-announcement on July 20, 2026 * Largest individual shareholder committed to tender all of its PolyPeptide shares into offer * Main offer period expected ...
Week's Top Stories
Most Reposted
Agoda and Emerging Travel Group Enter Strategic Partnership
[Picked up by 295 media titles]
2026-10-15 16:00Food & Hospitality Asia 2027 Redefining Excellence: The Premier Platform for Food & Beverage and Hospitality Innovation
[Picked up by 284 media titles]
2026-10-15 10:00Leading Asian DMC Discova to Attend ITB Asia 2026
[Picked up by 282 media titles]
2026-10-15 12:59SALMON SECURES $140 MILLION (PHP 8.8 BILLION) TO DOUBLE DOWN ON THE GROWTH OPPORTUNITY IN THE PHILIPPINES
[Picked up by 282 media titles]
2026-10-19 13:18Infobip and Yamaha Power Conversational Customer Engagement in Indonesia's Automotive Sector
[Picked up by 273 media titles]
2026-10-21 15:00